Bradley J. Bolzon PhD - Jun 11, 2021 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: Director
Signature: /s/ Robin L. Praeger, attorney-in-fact for Bradley Bolzon
Stock symbol: CRSP
Transactions as of: Jun 11, 2021
Transactions value $: -$1,266,118
Form type: 4
Date filed: 6/15/2021, 04:41 PM
Previous filing: Jun 14, 2021
Next filing: Jun 22, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRSP	Common Shares	Sale	-$682K	-5.43K	-17.87%	$125.62	24.9K	Jun 11, 2021	Direct	F1, F2
transaction	CRSP	Common Shares	Sale	-$243K	-1.92K	-7.69%	$126.59	23K	Jun 11, 2021	Direct	F1, F3
transaction	CRSP	Common Shares	Sale	-$102K	-800	-3.47%	$127.88	22.2K	Jun 11, 2021	Direct	F1, F4
transaction	CRSP	Common Shares	Sale	-$142K	-1.1K	-4.95%	$128.65	21.1K	Jun 11, 2021	Direct	F1, F5
transaction	CRSP	Common Shares	Sale	-$97.7K	-755	-3.57%	$129.45	20.4K	Jun 11, 2021	Direct	F1, F6
holding	CRSP	Common Shares						720K	Jun 11, 2021	See Footnote	F7
holding	CRSP	Common Shares						4.27K	Jun 11, 2021	See Footnote	F8
holding	CRSP	Common Shares						582K	Jun 11, 2021	See Footnote	F9
holding	CRSP	Common Shares						16.6K	Jun 11, 2021	See Footnote	F10
holding	CRSP	Common Shares						18.5K	Jun 11, 2021	See Footnote	F11
holding	CRSP	Common Shares						44.3K	Jun 11, 2021	See Footnote	F12
holding	CRSP	Common Shares						169K	Jun 11, 2021	See Footnote	F13

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $125.13 to $126.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3	The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $126.14 to $127.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
F4	The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $127.29 to $128.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
F5	The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $128.29 to $129.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
F6	The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $129.37 to $129.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.
F7	These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F8	These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F9	These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F10	These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F11	These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F12	These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
F13	These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.